Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA5A | P35218 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796681 | 0.85 | L3MBTL1 (0.49) | HRH3KCNH2 | |
| SCHEMBL6802876 | 0.84 | SIGMAR1 (0.55) | HRH3KCNH2MAOAMAOBSIGMAR1 | |
| SCHEMBL4803982 | 0.82 | HRH3 (0.47) | HRH3 | |
| SCHEMBL6802715 | 0.78 | HRH3 (0.52) | HRH3KDM4EALDH1A1OPRM1KCNH2 | |
| SCHEMBL6802717 | 0.78 | HRH3 (0.52) | HRH3KDM4EALDH1A1OPRM1KCNH2 | |
| SCHEMBL6807694 | 0.78 | HRH3 (0.52) | HRH3KDM4EALDH1A1OPRM1KCNH2 | |
| SCHEMBL14279324 | 0.78 | HRH3 (0.40) | HRH3KCNH2HTR2AHTR2C | |
| SCHEMBL6796914 | 0.77 | HRH3 (0.53) | HRH3ALDH1A1OPRM1KCNH2DRD2 | |
| SCHEMBL6796403 | 0.77 | ADRA1D (0.47) | HRH3ALDH1A1ADRA1AADRA1B | |
| SCHEMBL14279321 | 0.76 | HRH3 (0.47) | HRH3CHRM1DRD2CHRM3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320973-B2 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| EP-1475373-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1471060-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1403258-A1 | DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6528504-B2 | Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. | AJINOMOTO CO., INC. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | AJINOMOTO CO., INC. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1142884-A1 | OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | CYP3A4, PPARD, CYP4B1 | HRH3 518/4885KDM4E 924/4885CA12 4472/4885 |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | CACNG5, GRIK5, KCNB1 | HRH3 250/4885KDM4E 230/4885CA12 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.